Shandong Xinhua Pharmaceutical Company Limited

Equities

719

CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:35 2024-05-22 EDT 5-day change 1st Jan Change
5.73 HKD -0.52% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited -3.05% -0.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Xinhua Pharmaceutical's Depression Drug Gets Registration Approval in China MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit MT
Shandong Xinhua Pharmaceutical Proposes New Auditor MT
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes CI
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) CI
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China MT
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34% MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Xinhua Pharmaceutical’s AntiCoagulant Tablets Get Drug Registration Certificate MT
China Grants Marketing Approval for Shandong Xinhua Pharmaceutical's Uric Acid Medication; Shares Rise 4% MT
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat CI
Xinhua Pharmaceutical Unit's Clarithromycin Granules Passes Regulatory Evaluation MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration CI
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee CI
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 CI
Chart Shandong Xinhua Pharmaceutical Company Limited
More charts
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.
More about the company
  1. Stock Market
  2. Equities
  3. 719 Stock
  4. News Shandong Xinhua Pharmaceutical Company Limited
  5. Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation